Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $126.41 Consensus Target Price from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have earned an average recommendation of “Hold” from the eighteen brokerages that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $126.41.

Several equities analysts have recently weighed in on ZBH shares. Barclays cut their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a report on Friday, May 31st. Robert W. Baird cut their price target on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Canaccord Genuity Group lowered their price objective on shares of Zimmer Biomet from $130.00 to $120.00 and set a “hold” rating for the company in a research report on Tuesday, August 20th. Citigroup cut their price objective on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Finally, Evercore ISI dropped their price target on Zimmer Biomet from $115.00 to $113.00 and set an “in-line” rating on the stock in a research note on Thursday, August 8th.

Institutional Investors Weigh In On Zimmer Biomet

A number of institutional investors and hedge funds have recently modified their holdings of the company. OLD Point Trust & Financial Services N A acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at $26,000. Ables Iannone Moore & Associates Inc. acquired a new position in Zimmer Biomet in the 4th quarter valued at about $30,000. Crewe Advisors LLC bought a new position in Zimmer Biomet in the 1st quarter valued at about $31,000. Family Firm Inc. acquired a new stake in Zimmer Biomet during the second quarter worth approximately $33,000. Finally, J.Safra Asset Management Corp boosted its holdings in shares of Zimmer Biomet by 712.1% during the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 235 shares during the period. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Down 1.5 %

Shares of NYSE ZBH opened at $114.48 on Monday. Zimmer Biomet has a 52-week low of $102.00 and a 52-week high of $133.90. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.63 and a current ratio of 1.29. The stock has a market cap of $23.55 billion, a P/E ratio of 24.78, a P/E/G ratio of 2.06 and a beta of 1.01. The firm has a 50 day moving average price of $110.19 and a 200 day moving average price of $117.16.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.02. The company had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.94 billion. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The firm’s revenue was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.82 EPS. Analysts expect that Zimmer Biomet will post 8.06 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date of this dividend is Monday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.